Skip to main content
. 2014 Apr;3(2):156–182. doi: 10.3978/j.issn.2224-4336.2014.02.01

Table 3. New drug formulations for ALL therapy.

Drug Benefits
Pegylated asparaginase Long half-life, reduced immunogenicity (24)
Liposomal daunorubicin Decreased cardiotoxicity (25)
Liposomal annamycin Decreased cardiotoxicity (NCT00430443)
Sphingosomal vincristine Decreased neuropathy, high tissue concentration, non-vesicant (26)
Liposomal cytarabine Long half-life (27) (NCT00002704, NCT00991744)